满宝珍元治疗高血脂 高血压合并冠心病的临床疗效分析(1)
[摘要] 目的 探討满宝珍元治疗高血脂，高血压合并冠心病的临床疗效。方法 方便收集2013年2月—2015年8月长春医科医院高血脂、高血压合并冠心病的200例患者，分为100例研究组和100例对照组。对照组采取降压、降脂、降低血小板凝聚、营养心肌，研究组单纯采取满宝珍元治疗。对比①两组治疗前、治疗后心功能分级；②两组高血压治疗前后水平；③两组治疗期前后血脂水平；④两组复发率及治愈率对比。 结果 ①两组治疗前收缩压、舒张压分别为(155.4±14.9)mmHg、(94.2±7.5)mmHg和(156.1±15.1)mmHg、(92.1±6.7)mmHg，比较差异无统计意义(P>0.05)；两组治疗后高血压水平分别为(135.4±9.2)mmHg、(82.4±5.6)mmHg和(134.1±8.5)mmHg、(86.7±4.2)mmHg，比较差异有统计意义(P<0.05)。②研究组和对照组治疗前Ch、TG、LDL-C、BMI分别为(5.78±0.38)mmol/L、(2.54±0.36)mmol/L、(2.64±0.27)mmol/L、(25.46±1.21)kg/m2和(5.69±0.31)mmol/L、(2.56±0.38)mmol/L、(2.65±0.31)mmol/L、(25.49±1.35)kg/m2，差异无统计学意义(P>0.05)，研究组和对照组治疗后Ch、TG、LDL-C、HDL-C分别为(5.24±0.24)mmol/L、(2.37±0.28)mmol/L、(2.36±0.19)mmol/L、(24.69±1.18)kg/m2和(5.53±0.47)mmol/L、(2.49±0.35)mmol/L、(2.51±0.22)mmol/L、(25.31±1.28)kg/m2差异有统计学意义(P<0.05)。③研究组和对照组治愈率及复发率分别为(100%、0%)、(81%、18%)，比较差异有统计意义(P<0.05)。结论 满宝珍元单一用药比常规用药治疗高血脂，高血压合并冠心病疗效显著，应作为高血脂，高血压合并冠心病的首选治疗方法。
[关键词] 满宝珍元；高血脂；高血压；冠心病
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2016)12(c)-0001-03
[Abstract] Objective To investigate the treatment of high blood cholesterol with Manbaozhenyuan， the clinical curative effect of hypertension and coronary heart disease. Methods Convenient collected in February 2013 to August 2015 in Changchun Medical hospital high blood fat， high blood pressure and coronary heart disease 200 case patients， divided into 100 case research group and 100 case control group. The control group took antihypertensive and lipid-lowering， reduce platelet aggregation and myocardial nutrition， study group take full treatment of Manbaozhenyuan. Comparison ①Before and after treatment， the cardiac function of the two groups；②Before and after the treatment of hypertension in the two groups；③Blood lipid levels before and after treatment in the two groups；④The recurrence rate and cure rate of the two groups were compared. Results ①The two groups before treatment， systolic blood pressure and diastolic blood pressure were(155.4±14.9)mmHg，(94.2±7.5)mmHg，(156.1±15.1)mmHg，(92.1±6.7)mmHg (P>0.05)； there was no significant difference between the two groups after treatment of hypertension respectively (135.4±9.2)mmHg， (82.4±5.6)mmHg，(134.1±8.5)mmHg、 (86.7±4.2)mmHg had significant difference(P<0.05). ②Study group and control group before treatment， Ch， TG， LDL-C， BMI respectively (5.78±0.38)mmol/L， (2.54±0.36)mmol/L， (2.64±0.27)mmol/L， (25.46±1.21)kg/m2 and (5.69±0.31)mmol/L， (2.56±0.38)mmol/L， (2.65±0.31)mmol/L， (25.49±1.35)kg/m2，no difference statistical significance(P>0.05)， the study group and the control group after treatment Ch， TG， LDL-C， HDL-C respectively(5.24±0.24)mmol/L， (2.37±0.28)mmol/L， (2.36±0.19)mmol/L， (24.69±1.18)kg/m2 and (5.53±0.47)mmol/L， (2.49±0.35)mmol/L， (2.51±0.22)mmol/L，(25.31±1.28)kg/m2 the difference was statistically significant (P<0.05). ③the cure rate and recurrence rate of the study group and the control group were (100%， 0%)， (81%， 18%)， and there were differences(P<0.05). Conclusion Manbaozhenyuan should be used as the preferred method of treatment of high blood lipids， hypertension and coronary heart disease., 百拇医药(王宏双 孙思远 冀泓序 吴海涛 鲁宏伟)
[关键词] 满宝珍元；高血脂；高血压；冠心病
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2016)12(c)-0001-03
[Abstract] Objective To investigate the treatment of high blood cholesterol with Manbaozhenyuan， the clinical curative effect of hypertension and coronary heart disease. Methods Convenient collected in February 2013 to August 2015 in Changchun Medical hospital high blood fat， high blood pressure and coronary heart disease 200 case patients， divided into 100 case research group and 100 case control group. The control group took antihypertensive and lipid-lowering， reduce platelet aggregation and myocardial nutrition， study group take full treatment of Manbaozhenyuan. Comparison ①Before and after treatment， the cardiac function of the two groups；②Before and after the treatment of hypertension in the two groups；③Blood lipid levels before and after treatment in the two groups；④The recurrence rate and cure rate of the two groups were compared. Results ①The two groups before treatment， systolic blood pressure and diastolic blood pressure were(155.4±14.9)mmHg，(94.2±7.5)mmHg，(156.1±15.1)mmHg，(92.1±6.7)mmHg (P>0.05)； there was no significant difference between the two groups after treatment of hypertension respectively (135.4±9.2)mmHg， (82.4±5.6)mmHg，(134.1±8.5)mmHg、 (86.7±4.2)mmHg had significant difference(P<0.05). ②Study group and control group before treatment， Ch， TG， LDL-C， BMI respectively (5.78±0.38)mmol/L， (2.54±0.36)mmol/L， (2.64±0.27)mmol/L， (25.46±1.21)kg/m2 and (5.69±0.31)mmol/L， (2.56±0.38)mmol/L， (2.65±0.31)mmol/L， (25.49±1.35)kg/m2，no difference statistical significance(P>0.05)， the study group and the control group after treatment Ch， TG， LDL-C， HDL-C respectively(5.24±0.24)mmol/L， (2.37±0.28)mmol/L， (2.36±0.19)mmol/L， (24.69±1.18)kg/m2 and (5.53±0.47)mmol/L， (2.49±0.35)mmol/L， (2.51±0.22)mmol/L，(25.31±1.28)kg/m2 the difference was statistically significant (P<0.05). ③the cure rate and recurrence rate of the study group and the control group were (100%， 0%)， (81%， 18%)， and there were differences(P<0.05). Conclusion Manbaozhenyuan should be used as the preferred method of treatment of high blood lipids， hypertension and coronary heart disease., 百拇医药(王宏双 孙思远 冀泓序 吴海涛 鲁宏伟)